Tolerability and effectiveness of every-other-day atorvastatin compared to daily atorvastatin in patients with muscle symptoms: A randomized controlled clinical trial

Wijekoon, Nalaka; Wijekoon, S.; Bulugahapitiya, Uditha; Pathirana, Nethrani; Wickramasinghe, Malintha; Paranavitane, Shiran; Kottage, Arosha; Wijayawardena, Supun; Karunarathne, M.; Samarasinghe, Madusha; Sumanadasa, Subodha; Herath, Yanushka

doi:10.1016/j.conctc.2020.100685

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, is widely considered a lipid regulating drug [23,24]. However, atorvastatin has recently been demonstrated to have different pharmacological actions unrelated to its lipid-regulating effects.…”

Section: Discussionmentioning

confidence: 99%

Atorvastatin inhibits inflammation through the cysteine-rich motor neuron 1 (Crim1) pathway in human umbilical vein endothelial cells

Liu,

Wu,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background and AIMS: Inflammation has been recognized to have a role in the process of atherosclerosis. Although evidence indicates that atorvastatin has anti-inflammatory effects besides cholesterol-lowering ability in atherosclerosis, the specific mechanisms of atorvastatin in inflammation requires further discussion. METHODS: Here, we explored the effects and mechanisms of atorvastatin on inflammation in human umbilical vein endothelial cells through quantitative real-time PCR and western blot analyses. In addition, microarray analysis and immunohistochemistry were used to analyze the expression of Crim1 in atherosclerotic plaques. RESULTS: Cysteine-rich motor neuron 1 (Crim1) mRNA was upregulated 36.68 fold (P<0.001), and Crim1 protein was upregulated 3.63 fold (p<0.001), in human atherosclerotic plaques compared with normal intima tissues. Bioinformatics analysis revealed Crim1 co-expression with IL-6, TNF-α and NF-κB. Atorvastatin dramatically downregulated the mRNA and protein levels of Crim1 and inhibited inflammation by decreasing the levels of IL-6, TNF-α and NF-κB. Knockdown of Crim1 significantly inhibited IL-6, TNF-α and NF-κB expression, whereas overexpression of Crim1 upregulated IL-6, TNF-α and NF-κB expression. In addition, the inhibitory effects of atorvastatin on inflammation were markedly offset by overexpression of Crim1. CONCLUSION: These results demonstrated that atorvastatin decreases inflammation via the Crim1 pathway in HUVECs, thus, providing a new prospect for the use of atorvastatin for non-lipid lowering functions, and new directions for the prevention and therapy of atherosclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Atorvastatin inhibits inflammation through the cysteine-rich motor neuron 1 (Crim1) pathway in human umbilical vein endothelial cells

Liu,

Wu,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Lack of sensitivity to contemporary evidencebased recommendations and individual perspectives of possible side effects of statin such as muscle toxicity strengthened by the paucity of population-based evidence could have affected the substandard prescription pattern and low level of therapeutic target accomplishment. Several studies done in Sri Lanka have shown side effects of stains to be minimal [11]. Therefore, statins at the appropriate intensity should be prescribed to patients.…”

Section: Discussionmentioning

confidence: 99%

Utilization of statins in patients with type 2 diabetes mellitus: the practice in a lower middle income South Asian country

Matthias

Kaushalya

Somathilake

et al. 2022

Int J Diabetes Dev Ctries

View full text Add to dashboard Cite

Background Cardiovascular disease (CVD) is a major cause of morbidity and mortality among patients with type 2 diabetes. Statin reduces CVD risk. The ACC/AHA 2018 guideline on dyslipidemia recommends all patients with type 2 diabetes mellitus to be given moderate-intensity statin. We aimed to determine the prescription practices of statins among patients with type 2 diabetes mellitus. Methods A cross-sectional study was conducted from February to April 2021. Patients with type 2 diabetes mellitus between 40 and 75 years were recruited from the University Medical Clinic and Endocrine Clinic at

show abstract

Side effects of antilipid medications

Wells

Ezzet

Yamout

et al. 2021

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Tolerability and effectiveness of every-other-day atorvastatin compared to daily atorvastatin in patients with muscle symptoms: A randomized controlled clinical trial

Cited by 3 publications

References 33 publications

Atorvastatin inhibits inflammation through the cysteine-rich motor neuron 1 (Crim1) pathway in human umbilical vein endothelial cells

Atorvastatin inhibits inflammation through the cysteine-rich motor neuron 1 (Crim1) pathway in human umbilical vein endothelial cells

Utilization of statins in patients with type 2 diabetes mellitus: the practice in a lower middle income South Asian country

Side effects of antilipid medications

Contact Info

Product

Resources

About